Dimensional Fund Advisors LP Purchases 169,115 Shares of Abbott Laboratories $ABT

Dimensional Fund Advisors LP boosted its stake in Abbott Laboratories (NYSE:ABT) by 1.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,019,949 shares of the healthcare product maker’s stock after acquiring an additional 169,115 shares during the period. Dimensional Fund Advisors LP owned 0.52% of Abbott Laboratories worth $1,208,086,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $31,000. Anfield Capital Management LLC raised its position in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the period. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter worth $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABT. Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. BTIG Research decreased their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Oppenheimer dropped their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup decreased their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $113.55 on Wednesday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The firm has a market capitalization of $197.31 billion, a P/E ratio of 30.52, a P/E/G ratio of 1.82 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business’s 50-day moving average is $116.90 and its 200 day moving average is $125.00.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Activity at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. Company insiders own 0.46% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA cleared Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader intended to improve patient convenience and clinical workflow. The approval, together with existing reimbursement for implantable PA sensors, could boost physician adoption and revenue potential in Abbott’s cardiac portfolio. Abbott wins FDA approval for updated heart failure monitoring device How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Analyst commentary highlights reasons to like Abbott’s durable device franchises and margin profile but reiterates skepticism after the recent softer quarter that contributed to underperformance versus the S&P over the past six months. This keeps sentiment mixed until revenue and growth re‑acceleration are clearer. 2 Reasons to Like ABT and 1 to Stay Skeptical
• Negative Sentiment: Clustered insider selling: multiple senior executives sold a combined ~3,055 shares on March 2 at about $115.58 per share (notable filings from VP John McCoy, EVPs Mary Moreland, Daniel Salvadori, Elizabeth Cushman and SVP Eric Shroff). While the executives retain large holdings, concentrated sales can pressure sentiment near the sale price. SEC Form 4 (John A. Jr. McCoy)
• Negative Sentiment: Market reaction/price momentum — coverage and market notes report ABT shares have recently pulled back (near the mid‑$110s) after the quarter, which is reinforcing selling pressure in the near term. Investors are watching upcoming catalysts and whether CardioMEMS adoption lifts growth enough to reverse the trend. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why Abbott (ABT) Stock Sinks As Market Gains: Here’s Why (Zacks)

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.